Prevail InfoWorks

This inspiring article from Pfizer follows a patient named Eric through his clinical trial journey. For those looking to learn more about the clinical trial process, this is a great resource. “From the thousands of patients who volunteer each year to the scientists, clinicians, and principal investigators (PIs), each individual who contributes to a trial helps to bring about life-changing treatments and advances our knowledge of diseases.” #ClinicalTrials #Patients #Safety #Discovery https://lnkd.in/eUQEb2bn

Gilead Sciences partners with Genesis Therapeutics in a $35M collaboration to accelerate AI-driven drug discovery? ? Genesis’ innovative GEMS AI platform continues to capture attention, now attracting Gilead Sciences to its growing list of partners. With this new collaboration, Gilead is investing $35M upfront for AI-based drug discovery on three undisclosed targets. This marks Genesis’ third major pharma partnership, following previous deals with Genentech and Eli Lilly. Together, Gilead and Genesis aim to revolutionize the discovery of treatments for difficult protein targets by harnessing the power of generative AI.? Did you know there is also AI for the clinical development process? By automatically harnessing, consolidating and reconciling study data, while a study is ongoing, Prevail InfoWorks delivers predictive analytics, confirmatory clinical observations early, and the fastest trend analyses and reporting. To learn more about this and other technologies in clinical development, access Prevail InfoWorks’ proven track record here: https://lnkd.in/e2wWMMej "Needs are diverse and ever-changing, and that’s why we are committed to staying ahead of the curve, anticipating trends, and delivering solutions that exceed expectations." stated Jack Houriet, CEO of Prevail InfoWorks. How do you think AI is transforming the future of our life sciences industry and will it overcome the inefficiencies and burdensome processes? Read more in the comment section. #DrugDiscovery #Biotechnology #GileadSciences #GenesisTherapeutics #PharmaInnovation #HealthcareAI #ClinicalResearch #ArtificialIntelligence #RDCollaboration

Breaking New Ground: Eli Lilly and Haya Therapeutics Team Up in $1B Obesity Treatment Deal Exciting news from Eli Lilly and Company as they expand their focus on obesity treatment through a $1 billion partnership with HAYA Therapeutics. This collaboration leverages Haya's cutting-edge technology to target long noncoding RNAs (lncRNAs), which play a key role in regulating gene expression and could open doors to next-generation obesity therapies. Lilly is working to maintain its early lead by securing multiple deals aimed at developing next-generation obesity treatments. With this move, Lilly continues to position itself at the forefront of innovative weight management solutions. As things shake up further in weight management therapies, what might this deal mean for the future of obesity R&D? Will we see even bigger partnerships in the future? “By identifying disease-driving cell states and novel lncRNA therapeutic targets, Haya’s proprietary regulatory genome discovery platform may pave the way for the development of genetic medicine therapies that modify disease cell states, augmenting the efficacy of current obesity targeting therapies,” says Haya’s CEO Samir Ounzain. Feel free to check out the article linked in the comments below. #Obesity #ObesityTreatment #PharmaInnovation #GeneticMedicine #RNA #lncRNA #BiotechPartnership #HealthcareR&D #NextGenTherapies #WeightManagement #EliLilly #HayaTherapeutics #Biopharma #ObesityResearch #PrecisionMedicine #RNAtherapeutics #LifeSciences

From Rare to Routine: Gene Therapy’s Visionary Approach to Fighting Blindness in the Elderly Can you imagine what it would feel like to regain the gift of sight after years of darkness with just a single treatment? Gene therapy is on the verge of transforming treatment for wet age-related macular degeneration (AMD), the leading cause of blindness in older adults. According to American Foundation for the Blind (AFB), 2.2% of Americans 65 to 74 years of age reported having vision loss, and 15.2% of Americans 75 years of age and over reported having vision loss.?Vision loss can be linked to cognitive impairment and dementia. REGENXBIO Inc. and AbbVie’s candidate ABBV-RGX-314, uses an AAV8 vector to deliver a gene that encodes an anti-VEGF antibody fragment. Adverum Biotechnologies uses intravitreal injections, and it has shown a 90% reduction in the need for annual injections. The most familiar method, used by Adverum and 4D Molecular Therapeutics, mimics current treatment methods but aims for long-term efficacy. With advancements from companies like REGENXBIO, AbbVie, 4D Molecular Therapeutics (4DMT) and Adverum, these innovative approaches could offer a long-term solution, significantly reducing the burden of ongoing treatments. It could lead to widespread adoption, providing a new standard of care for wet AMD. Read more in the comment section #GeneTherapy #WetAMD #VisionCare #Biotechnology #Healthcare #Innovation #ElderlyCare #RegenerativeMedicine #ClinicalTrials #Ophthalmology #MedicalBreakthrough

A Promising Step Forward in Rare Blood Vessel Disorder Treatment Vaderis Therapeutics AG has achieved a significant milestone in its quest to combat hereditary hemorrhagic telangiectasia (HHT), a rare and debilitating blood vessel disorder. According to Centers for Disease Control and Prevention (CDC), HHT causes the formation of abnormal, fragile blood vessels that can burst and lead to bleeding. This disorder can result in anything from frequent nosebleeds to life-threatening complications.? Their allosteric AKT inhibitor, VAD044, has shown promising results in reducing the frequency of nosebleeds—a common and often severe symptom of HHT. In a recent Phase 1 trial, VAD044 demonstrated a favorable safety profile, with patients experiencing "clinically meaningful" reductions in nosebleeds after 12 weeks. The ongoing open-label extension continues to show further improvements, bringing hope to those affected by this challenging condition. As Vaderis moves forward with pivotal development, this advancement represents a beacon of hope for the HHT community. “The excitement surrounding the results of the initial 12-week double-blind part of this trial is amplified by the continued improvements experienced by patients through six months,” CEO of Vaderis Therapeutics Nicholas Benedict added. Did you know that HHT affects about 1 in 5,000 to 10,000 people and children of a person with HHT and their siblings have a 50% chance of inheriting the condition? Read more in the comment section. #Biotechnology #Healthcare #ClinicalTrials #RareDisease #DrugDevelopment #HHT #VascularHealth #GeneticDisorders #PatientCare #MedicalResearch?

Big Bucks: Adcendo’s $1 Billion Cancer Bet on ADC Technology Exciting news coming from Denmark's Adcendo: The biotech company has struck a major deal worth up to $1 billion with Multitude Therapeutics for the ex-China rights to ADCE-T02, a promising preclinical antibody-drug conjugate (ADC). The first-in-class ADC is set to begin a phase 1 trial in Australia later this year, with plans for a U.S. study soon after. This innovative ADC, featuring a topoisomerase I inhibitor-based linker/payload, is designed to target solid tumors with precision, offering hope for improved safety profiles and better outcomes for cancer patients. Do you know many phase 1 deals done for a billion dollars? “We are highly impressed by the deep science behind Multitude Therapeutics’ linker/payload platforms and are delighted about our licensing agreement on ADCE-T02, which perfectly complements our existing unique first-in-class ADC pipeline and allows Adcendo to become a clinical-stage biotech company in Q4 2024,” says Michael Pehl, Adcendo CEO. Feel free to check out the article linked in the comments below. #BiotechInnovation #CancerResearch #ADCTechnology #PharmaDeals #OncologyBreakthrough #PrecisionMedicine #LifeSciences #ClinicalTrials #Biotechnology #PharmaPartnerships #HealthcareInnovation #FutureOfMedicine #Adcendo #MultitudeTherapeutics

Pathalys Pharma Secures $105M Series B to Drive Kidney Disease Drug to FDA Approval Pathalys Pharma investors have made a bold move in the fight against kidney disease, providing $105 million in a Series B funding round to push Pathalys’s lead drug, upacicalcet, toward FDA approval. This innovative calcimimetic, already a success in Japan, could revolutionize the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. With these new funds, Pathalys is poised to complete two critical Phase 3 trials and ramp up pre-approval preparations. This milestone reflects strong investor confidence in Pathalys' mission to deliver cutting-edge therapies for end-stage kidney disease. Share your thoughts on this significant funding milestone and its potential impact on kidney disease treatments. Read more in the article in the comment section. “Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet,” Pathalys CEO Neal Fowler said in the Aug. 20 release. #KidneyHealth #Biotech #PharmaNews #ClinicalResearch #HealthcareFunding #MedicalAdvancements #FDAApproval #ChronicKidneyDisease #HealthcareInvestments #LifeSciences

Milestone Achieved: FDA Greenlights Gilead's Newly Poised “Livdelzi” to Make a Big Impact Perhaps you caught our previous LinkedIn post that was shared by us 2 months ago. As it happens, what we’ve been hoping for has come to fruition. Gilead Sciences has now received FDA approval for Livdelzi (seladelpar), a new treatment for a rare liver disease known as primary biliary cholangitis. This approval is crucial for patients who can’t tolerate or don't respond well to existing treatments. Livdelzi is now available alone or in combination with other therapies and has strong potential in the market. How will Livdelzi's FDA approval reshape the options available for patients with primary biliary cholangitis? RBC Capital Markets analyst Brian Abrahams noted that Livdelzi's "cleaner label and itch relief benefits" are likely to give it a competitive advantage. Feel free to check out the article linked in the comments below. ? #Livdelzi #FDAApproval #PrimaryBiliaryCholangitis #GileadSciences #Biotech #Pharma #HealthcareInnovation #LiverDisease #NewTreatment #CymaBayTherapeutics #DrugDevelopment #MarketImpact #MedicalBreakthrough

Halda’s $126M Power Move: Revolutionizing Cancer Treatment with ‘Hold and Kill’ Technology Innovative strides in cancer treatment are on the horizon. Halda Therapeutics has secured a substantial $126 million in Series B funding to propel its pioneering RIPTAC program into clinical trials. RIPTAC, which stands for Regulated Induced Proximity Targeting Chimeras, represents a novel “hold and kill” mechanism that promises to target and eliminate cancer cells while sparing healthy tissue. This funding will fuel the advancement of HLD-0915, set to enter a Phase 1 trial for metastatic, castration-resistant prostate cancer in the first half of next year. Halda’s breakthrough approach could potentially overcome drug resistance—a significant hurdle in current cancer therapies. This “oral, selective, and widely applicable cancer cell-killing mechanism … is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Halda Chief Scientific Officer Kat Kayser-Bricker, Ph.D., explained in an Aug. 12 release. The future of oncology is looking brighter with each step forward. How do you think Halda’s ‘hold and kill’ approach could reshape the future of cancer treatment? Read more in the article in the comment section. #Oncology #Biotech #CancerResearch #Innovation #Healthcare #VentureCapital

$700M Deal: Can Merck’s CN201 Disrupt the Oncology and Autoimmune Markets? ? Merck is stepping into the blood cancer market with a $700 million upfront deal to acquire global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific candidate, CN201. This move positions Merck as a strong competitor against Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune diseases. Early clinical data shows promising results in non-Hodgkin lymphoma and acute lymphoblastic leukemia, with a focus on reducing cytokine release syndrome. Merck is committed to advancing CN201 in B-cell malignancies and exploring its potential in autoimmune conditions. How do you see Merck’s acquisition of CN201 impacting the competitive landscape in both oncology and autoimmune disease treatment? Did you find this move on Merck’s part surprising? “Autoimmune diseases are on Merck’s roadmap for CN201. Interest in targeting CD19 has intensified in recent years as researchers have published data on a CAR-T candidate in lupus,” says Fierce Biotech writer Nick Paul Taylor. Read more in the article in the comment section. #Acquisition #Oncology #Autoimmune #Biotech #Pharma #CancerResearch #BloodCancer #HealthcareInnovation #PharmaDeals #ClinicalTrials #CN201 #MedicalResearch #CD19 #HealthcareIndustry